Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage

American Journal of Hypertension

Volumn 22, Issue 3, 2009, Pages 257-262

  Notsu, Yoshitomo ^a   Nabika, Toru ^a,b   Bokura, Hirokazu ^a,b   Suyama, Yoji ^a   Kobayashi, Shotai ^a,b   Yamaguchi, Schuhei ^a,b   Masuda, Junichi ^a,b  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Shimane Institute of Health Science   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DIMETHYLARGININASE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; SYMMETRIC DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BRAIN DAMAGE; CONTROLLED STUDY; EVALUATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MICROANGIOPATHY RELATED CEREBRAL DAMAGE; PRIORITY JOURNAL;

ARGININE; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRAIN DAMAGE, CHRONIC; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERTENSION; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; ODDS RATIO; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 60549096642     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.346     Document Type: Article

References (50)

1. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002; 13(suppl 2):7-10.
2. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci 1997; 152:15-21.
3. Schmidt R, Schmidt H, Kapeller P, Lechner A, Fazekas F. Evolution of white matter lesions. Cerebrovasc Dis 2002; 13(suppl 2):16-20.
4. Hassan A, Gormley K, O'Sullivan M, Knight J, Sham P, Vallance P, Bamford J, Markus H. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke 2004; 35:654-659.
5. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis 2002; 13(suppl 2):11-15.
6. Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, Higuchi S, Matsushita S, Morikawa M, Kato A, Sasaki H. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32:1116-1119.
7. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, DeCarli C. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 2005; 36:1207-1211.
8. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals: correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996; 27:2043-2047.
9. Schmidt H, Fazekas F, Kostner GM, van Duijn CM, Schmidt R. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 2001; 32:405-412.
10. Notsu Y, Nabika T, Park H-Y, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke 1999; 30:1881-1886.
11. Shibata H, Nabika T, Moriyama H, Masuda J, Kobayashi S. Correlation of NO metabolites and 8-iso-prostaglandin F2α with periventricular hyperintensity severity. Arterioscler Thromb Vasc Biol 2004; 24:1659-1663.
12. Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 1994; 14:175-192.
13. Nasreen S, Nabika T, Shibata H, Moriyama H, Yamashita K, Masuda J, Kobayashi S. T-786C polymorphism in endothelial NO synthase gene affects cerebral circulation in smokers: possible gene-environmental interaction. Arterioscler Thromb Vasc Biol 2002; 22:605-610.
14. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024-2029.
15. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24:1023-1030.
16. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24:611-619.
17. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
18. Valkonen VP, Laakso J, Päivä H, Lehtimäki T, Lakka TA, Isomustajärvi M, Ruokonen I, Salonen JT, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 2001; 358:2127-2128.
19. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33:652-658.
20. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101:856-861.
21. Fang Y, Mu J-J, He L-C, Wang S-C, Liu Z-Q. Salt loading on plasma asymmetric dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive Asians. Hypertension 2006; 48:724-729.
22. Yoo J-H, Lee S-C. Elevated levels of plasma homotyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158:425-430.
23. Wanby P, Teerlink T, Brudin L, Brattström L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke ant TIA in a Swedish population. Atherosclerosis 2006; 185:271-277.
24. Khan U, Hassan A, Vallance P, Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38:411-413.
25. Segarra G, Medina P, Ballester RM, Lluch P, Adcasoro M, Vila JM, Lluch S. Effects of some guanidine compounds on human cerebral arteries. Stroke 1999; 30:2206-2211.
26. Jung CS, Iuliano BA, Harvey-White J, Espey MG, Oldfield EH, Pluta RM. J Neurosurg 2004; 101:832-842.
27. Jin J-S, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996; 28:439-446.
28. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. New Engl J Med 1998; 338:1042-1050.
29. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29:2473-2477.
30. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-1398.
31. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069-1075.
32. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, Imano H, Ohira T, Okamura T, Naito Y, Shimamoto T. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109:2766-2772.
33. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl 2003; 4:61-65.
34. Stuhlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569-2575.
35. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20:1557-1564.
36. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetric dimethylarginine ratio. Pharmacol Ther 2007; 114:295-306.
37. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219:598-603.
38. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11:41-50.
39. Dobashi Y, Santa T, Nakagomi K, Imai K. An automated analyzer for methylated arginines in rat plasma by HPLC with post-column fluorescence reaction. Analyst 2002; 127:54-59.
40. Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Bertha G, Lechner H. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988; 19:1285-1288.
41. Smestad C, Sandvik L, Homoy T, Harbo HF, Celius EG. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol 2008; 255:49-55.
42. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006; 21:2446-2451.
43. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetric dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17:1128-1134.
44. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005; 43:1130-1138.
45. Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA) - a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17:55-59.
46. Wilcken DEL, Wang J, Sim AS, Green K, Wilcken B. Asymmetric dimethylarginine in homocystinuria due to cystathionine β-synthase deficiency: relevance of renal function. J Inherit Metab Dis 2006; 29:30-37.
47. Pezzini A, Del Zotto E, Padovani A. Homocysteine and cerebral ischemia: pathogenic and therapeutical implication. Curr Med Chem 2007; 14:249-263.
48. Van Guldener C. Homocysteine and the kidney. Curr Drug Metab 2005; 6:23-26.
49. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. Kidney Blood Press Res 2008; 31:259-267.
50. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease not validated. J Am Coll Cardiol 2006; 48:914-923.